Mifomet (Metformin Hydrochloride, Sitagliptin)

Metformin hydrochloride lowers hepatic glucose production and improves peripheral insulin sensitivity. Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises endogenous incretin levels and enhances glucose‑dependent insulin secretion. Together they provide complementary mechanisms to improve overall glycemic control.

The exact dose of Mifomet is determined by the prescribing healthcare professional based on the individual’s renal function, glycemic targets, and concomitant therapies. Clinicians typically start with a low dose and titrate as needed, following local prescribing guidelines.

Safety data for Mifomet in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To order Mifomet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mifomet combines two established agents—metformin and sitagliptin—into a single tablet, offering the convenience of fixed‑dose therapy. Compared with taking the drugs separately, it reduces pill burden and may improve adherence. Alternatives such as metformin plus a different DPP‑4 inhibitor or a GLP‑1 receptor agonist have similar efficacy but differ in dosing frequency, side‑effect profile, and cost.

Mifomet tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Mifomet is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a full glass of water and not chewed or crushed unless specifically advised.

The most serious adverse events to monitor are lactic acidosis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), acute pancreatitis, and significant renal or hepatic impairment. Prompt medical attention is required if symptoms such as unexplained fatigue, abdominal pain, or rapid breathing occur.

Mifomet is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, a history of lactic acidosis, or acute or chronic metabolic acidosis. Caution is also advised for those with significant hepatic disease.